Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
J Infect Dis. 2021 09 17; 224(6):989-994.JI

Abstract

The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.

Authors+Show Affiliations

Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom.Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom.Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom.Department of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, Miyazaki,Japan.Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom.National Centre for Disease Control, Delhi,India.Department of Hematology and Oncology, Kyoto University, Kyoto,Japan.Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.Department of Hematology and Oncology, Kyoto University, Kyoto,Japan.Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom.CSIR Institute of Genomics and Integrative Biology, Delhi,India.Department of Pathology, National Institute of Infectious Diseases, Tokyo,Japan.Department of Pathology, National Institute of Infectious Diseases, Tokyo,Japan.Division of Systems Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. CREST , Japan Science and Technology Agency, Saitama,Japan.Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge,United Kingdom. Department of Medicine, University of Cambridge, Cambridge,United Kingdom. Africa Health Research Institute, Durban,South Africa.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34260717

Citation

Ferreira, Isabella A T M., et al. "SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion." The Journal of Infectious Diseases, vol. 224, no. 6, 2021, pp. 989-994.
Ferreira IATM, Kemp SA, Datir R, et al. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. J Infect Dis. 2021;224(6):989-994.
Ferreira, I. A. T. M., Kemp, S. A., Datir, R., Saito, A., Meng, B., Rakshit, P., Takaori-Kondo, A., Kosugi, Y., Uriu, K., Kimura, I., Shirakawa, K., Abdullahi, A., Agarwal, A., Ozono, S., Tokunaga, K., Sato, K., & Gupta, R. K. (2021). SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. The Journal of Infectious Diseases, 224(6), 989-994. https://doi.org/10.1093/infdis/jiab368
Ferreira IATM, et al. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. J Infect Dis. 2021 09 17;224(6):989-994. PubMed PMID: 34260717.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. AU - Ferreira,Isabella A T M, AU - Kemp,Steven A, AU - Datir,Rawlings, AU - Saito,Akatsuki, AU - Meng,Bo, AU - Rakshit,Partha, AU - Takaori-Kondo,Akifumi, AU - Kosugi,Yusuke, AU - Uriu,Keiya, AU - Kimura,Izumi, AU - Shirakawa,Kotaro, AU - Abdullahi,Adam, AU - Agarwal,Anurag, AU - Ozono,Seiya, AU - Tokunaga,Kenzo, AU - Sato,Kei, AU - Gupta,Ravindra K, AU - ,, AU - ,, PY - 2021/07/12/received PY - 2021/07/13/accepted PY - 2021/7/15/pubmed PY - 2021/9/30/medline PY - 2021/7/14/entrez KW - B.1.617 KW - COVID-19 KW - Indian variant KW - SARS-CoV-2 KW - antibody escape KW - evasion KW - fitness KW - infectivity KW - neutralizing antibodies KW - resistance KW - spike mutation SP - 989 EP - 994 JF - The Journal of infectious diseases JO - J Infect Dis VL - 224 IS - 6 N2 - The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity. SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/34260717/SARS_CoV_2_B_1_617_Mutations_L452R_and_E484Q_Are_Not_Synergistic_for_Antibody_Evasion_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiab368 DB - PRIME DP - Unbound Medicine ER -